Identification of PLCγ2 activators for the treatment of Alzheimer’s disease
Activation of PLCγ2 is a novel therapeutic strategy for treatment of AD. We identified structurally distinct molecular scaffolds capable of enzyme activation and cellular activity. Recommendations for use of probe molecules in target validation studies and the development of lead-like molecules for clinical studies will be made.
Authors
- Alan D. Palkowitz
- Andrew D. Mesecar (ORCID: https://orcid.org/0000-0002-1241-2577)
- Steven M Massey
- Bridget Kaiser
- Stephanie J. Bissel (ORCID: https://orcid.org/0000-0002-7376-2327)
- Emma K. Lendy (ORCID: https://orcid.org/0000-0003-0619-8743)
- Emily R. Mason
- Logan M. Bedford
- Shaoyou Chu
- Stacey J Sukoff Rizzo
- Bruce T. Lamb
- Timothy I. Richardson
- Brent Clayton
Institutions
- University of Pittsburgh (US)
- Purdue University West Lafayette (US)
- Indiana Biosciences Research Institute (US)
- Indiana University School of Medicine
- Indiana University – Purdue University Indianapolis (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70859_103518
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00